TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Potential Benefits of Laser Treatment on Skin Blood Flow and Sweating in Burn Survivors

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18-65 years old~* Experience a severe burn injury that warrant laser therapy.~* Free of any significant underlying medical problems based upon a detailed medical history and physical exam~Exclusion Criteria:~* Known heart disease~* Other chronic medical conditions requiring regular medical therapy including cancer, diabetes, uncontrolled hypertension, and uncontrolled hypercholesterolemia.~* Abnormality detected on routine screening suggestive of cardiac ischemia or previously undetected cardiac disease or resting left bundle branch block on screening electrocardiogram.~* Subject with a body mass index \>35 kg/m2~* Pregnant or planning to become pregnant within the subsequent 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Standard Drug Therapy vs. Implanted Defibrillator for Primary Prevention of Sudden Cardiac Death

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* documented chronic coronary heart disease (prior MI and/or angiographically documented CAD), \> 40 days post the most recent MI;~* LVEF \< 40% (by MUGA) and NYHA functional class II or III at time of assessment OR LVEF ≤ 35 % (by MUGA) and NYHA functional class I, II or III at time of assessment~* Judged to have a reasonable expectation of survival with a good functional status for more than 1 year, as well as receiving optimum, guideline recommended therapy for coronary artery disease and heart failure (or demonstrated intolerance or contraindications to such therapy).~* Age ≥ 18 years; no upper age limitation.~Exclusion Criteria:~* Prior cardiac arrest, sustained VT or VF, or unexplained syncope.~* Attempted VT / VF induction at electrophysiological study.~* Need for a cardiac resynchronization therapy (CRT) device.~* Enrollment in another interventional trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): None
- 2 (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Health Status and Quality of Life in the Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females 65-85 years old~* ECOG Performance score 0 to 1~* Body mass index 22-30 kg/m2~* Body weight \>60 kg~* Habit to consume standard breakfast like toast, bread, butter/margarine, eggs, bacon, cereals with milk~* Comply with protocol and likely to be compliant with prescribed product~Exclusion Criteria:~* Renal insufficiency or failure at screening~* Current or previous positive documented history of any chronic inflammatory state including chronic infection, arthritis, or collagen vascular disorder.~* Comorbid medical conditions~* Use of prescription medication for chronic conditions~* Use of hormone replacement therapy (with the exception of levothyroxine)~* Uncontrolled hypertension~* Use of hemostatic agents~* Hemorrhagic disorder and/or coagulation disorder~* Clinically important bleeding within 90 days prior to screening visit~* Fat malabsorption syndromes~* Constipation and/or abdominal pain/discomfort that require dietary supplements or medical therapy~* History of smoking within 1 year prior to visit 1.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Placebo capsules (Type: PLACEBO_COMPARATOR): Placebo capsules
- AMP-886 (alpha-tocotrienol) in capsules (Type: EXPERIMENTAL): AMP-886 (alpha-tocotrienol) in capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Glucose Uptake in Metabolic Tissues After Bariatric Surgery

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMI 35.0-50.0 kg/m2 for obese group and 18.5-24.9 kg/m2 for the lean group~* Must be scheduled for RYGB or SG surgery~Exclusion Criteria:~* Previous bariatric surgery~* Unstable weight (\>4% change during the last 2 months before entering the study)~* Significant organ system dysfunction (e.g., severe pulmonary or kidney disease)~* Cancer or cancer that has been in remission for \<5 years~* Conditions that render subject unable to complete all testing procedures (e.g. metal implants that interfere with imaging procedures; coagulation disorders)~* Use of medications that are known to affect the study outcome measures or increase the risk of study procedures and that cannot be temporarily discontinued for this study~* Pregnant or lactating women~* Persons who are not able to grant voluntary informed consent~* Persons who are unable or unwilling to follow the study protocol or who, for any reason, the research team considers not an appropriate candidate for this study, including non-compliance with screening appointments or study visits

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- RYGB or SG (Type: EXPERIMENTAL): Baseline testing followed by subject's already scheduled RYGB or SG surgery, and then post-testing.
- Lean (Type: NO_INTERVENTION): Lean control subjects doing baseline testing only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Chronic Sildenafil for Severe Diaphragmatic Hernia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Congenital diaphragmatic hernia~* 10-42 days (d) of age~* Significant illness severity as demonstrated by:~* Receiving assisted ventilation and~  * FiO2 \>= 0.40 at 10-14d of age, or~ * FiO2 \>= 0.40 for \>=48hours at 15-27d of age, or~ * FiO2 \>= 0.35 at 28-42d of age~* Or, need for extracorporeal support at \>=10d of age~* Or, estimated pulmonary arterial or right ventricular systolic pressure of \>= 2/3 systemic pressure at 14-42d of age~Exclusion Criteria:~* Structural congenital heart disease (other than patent ductus arteriosus or patent foramen ovale/atrial septal defect \[ASD\] or non-hemodynamically significant ventricular septal defect \[VSD\])~* Sildenafil contraindicated (until condition resolves):~  * Unable to absorb oral medication, or~ * Unstable systemic blood pressure, or~ * Receiving a drug that may interfere with sildenafil metabolism, or~ * Renal insufficiency~ * Hepatic insufficiency Previous use of sildenafil

- Gender: ALL
- Minimum Age: 10 Days
- Maximum Age: 42 Days
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Sildenafil x 45 days
- 2 (Type: PLACEBO_COMPARATOR): Placebo x 45 d

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Beta Blockers Versus Variceal Band Ligation and Beta Blockers for Primary Prophylaxis of Variceal Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* cirrhosis~* medium to large varices~Exclusion Criteria:~* contraindications to beta blockers~* refusal to give consent~* prior history of variceal hemorrhage~* creatinine \> 1.5 mg/dl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): endoscopic variceal band ligation
- 2 (Type: ACTIVE_COMPARATOR): subjects will receive nadolol (beta blocker) at 20mg/day with dose titration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who are candidates for routine, uncomplicated cataract surgery.~* Subjects must be willing to wait to undergo cataract surgery on the fellow eye until after the study has been completed.~Exclusion Criteria:~* Subjects who are expected to require treatment with any systemic or ocular (either eye) drugs specified in the protocol during the 18 days following cataract surgery or any systemic or ocular corticosteroids within 14 days prior to cataract surgery.~* Subjects who have known hypersensitivity or contraindication to the study drug(s) or their components.~* Subjects who have a severe/serious ocular condition or history/presence of chronic generalized systemic disease that the Investigator feels might increase the risk to the subject or confound the result(s) of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mapracorat (Type: EXPERIMENTAL): Mapracorat ophthalmic suspension
- Vehicle (Type: PLACEBO_COMPARATOR): Vehicle of mapracorat ophthalmic suspension

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of a Technology-Based Treatment Support System

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* English-speaking~* Currently enrolled in outpatient treatment~* Current diagnosis of major depressive disorder~* Ownership of a smartphone device compatible with the mobile app~Exclusion Criteria~* visual, hearing, voice, or motor impairment that would prevent completion of the study procedures or use of mobile phone~* diagnosis of a psychotic disorder, bipolar disorder, dissociative disorder, substance use disorder, or other diagnosis for which participation in this trial is inappropriate, severe suicidality (has ideation, plan, and intent).~* having completed more than 3 sessions of psychotherapy with current therapist

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mobile App (Type: EXPERIMENTAL): Participants will receive a mobile app to be used during psychotherapy that syncs information with the participant's therapist from sessions.
- Treatment as Usual (Type: NO_INTERVENTION): Participants will receive treatment as usual with aspects of the mobile app available through paper-based worksheets.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Creation of an ECG Database in 3T MRI With Healthy Heart and Several Kind of Cardiac Disease.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* For all subjects:~  * To be more than 18~ * To be enroled in a social security plan~ * To have signed an informed consent~ * To have preliminary medical examination~* For the groups :~  * normal ECG group : sinus rhythm without conductive troubles. Normal pattern of the QRS~ * conductive troubles group : patients with typical right bundle branch block, or typical left bundle branch block pattern.~ * rhythm trouble group : patients with premature atrial beats or premature ventricular beats~Exclusion Criteria:~* Contraindication: implantable devices (cardiac stimulators, defibrillators, cochlear implants, etc.), metallic foreign bodies~* Impossibility to undergo MRI: claustrophobia, morbid obesity.~* Pregnancy or risk of pregnancy.~* Patients under a measure of legal protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Patients with conductive troubles (Type: OTHER): Patients with conductive troubles
- Patients with rhythm troubles (Type: OTHER): Patients with rhythm troubles
- Volunteers (Type: OTHER): Volunteers with normal ECG

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Recording and Modulation of Brain Activity Through Chronically Implanted Stimulation Electrodes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age: 18 years old or more~* Informed Consent as documented by signature~* Diagnosed with Parkinson's disease, and being treated with deep brain stimulation therapies.~* Exhibiting severe locomotor deficits~* Agree to comply in good faith with all conditions of the recordings.~Exclusion Criteria:~* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,~* Participation in another investigational study in the preceding 30 days~* Previous enrolment into the current study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: HFNC vs LFNC in Patients With AF Undergoing RFCA Under Deep Sedation.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults undergoing an elective RFCA for atrial fibrillation in the Maastricht UMC Cardiac Catheter Labs under deep sedation administered by a clinician anesthesiology~Exclusion Criteria:~* Age under 18 years~* Body Mass Index (BMI) \> 32 kg/m²~* Diagnosed Sleep Apnoea Syndrome (SAS)~* Chronic Pulmonary Obstructive Disease (COPD) gold IV and COPD gold III with frequent or recent exacerbation~* Diagnosed pulmonary or cardiac condition requiring chronic oxygen therapy~* Complete nasal obstruction~* Active nose bleeding~* Untreated pneumothorax (pre- existing)~* Recent upper airway surgery~* Recent base of skull fracture~* Expected difficult airway

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High flow nasal cannula (Type: EXPERIMENTAL): Participants in the high flow nasal cannula group will receive high flow nasal cannula oxygen during deep sedation.
- Low flow nasal cannula (Type: NO_INTERVENTION): Participants in the current standard of care will receive low flow nasal cannula during deep sedation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Disease statue: NHL, HD, or MM that are chemorefractory or relapsed; CLL that is Rai Stage III/IV, or lymphocyte doubling time of 6 months, or stage I/II that is resistant to \> 2 chemotherapy regimens; AML or ALL in 1st or subsequent remission with poor prognostic features; CML in accelerated or blast phae; MDS with life-threatening cytopenias; patients who have had a previous autologous or allogeneic bone marrow or stem cell transplant; other hematologic disorders which allogeneic stem cell transplantation is appropriate where the risk of conventional transplantation is considered to be unacceptably high.~* Estimated disease-free survival of less than one year~* ECOG performance status of 0, 1, or 2~* HLA-genotypically or phenotypically matched (at A, B, DR loci) related donor~Exclusion Criteria:~* Patients who life expectancy is limited by diseases other than their hematologic malignancy.~* Cardiac Disease: symptomatic congestive hearth failure, or RVG, or ejection fraction of \< 45%, active angina pectoris, or uncontrolled hypertension.~* Pulmonary Disease: severe chronic obstructive lung disease, or symptomatic restrictive lung disease, or DLCO of \< 50%.~* Renal Disease: serum creatinine \> 2.0 mg/dl or creatinine clearance \< 50 ml/min.~* Hepatic Disease: serum bilirubin \> 2.0 mg/dl or alkaline phosphatase, SGOT or SGPT \> 3 times normal.~* Neurologic Disease: symptomatic leukoencephalopathy, active CNS malignancy or other neuropsychiatric abnormalities believed to preclude transplantation~* HIV or HTLV I antibody or Hepatitis B surface antigen positivity~* Uncontrolled infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Transplantation (Type: EXPERIMENTAL): T-cell depleted HLA-matched peripheral blood stem cell transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability of Full Dose Enteric-coated Mycophenolate Sodium, in Addition to Cyclosporine for Microemulsion Reduced Dose, in Maintenance Renal Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Male or female recipients of single or double renal transplant performed since at least one year and no more that 5 years~* Age \> 18 yrs~* Adequate and stable renal function~* Informed consent.~Exclusion criteria:~* Kidney transplant combined with other organs;~* Significant proteinuria~* Severe ongoing infections;~* Present or historical malignant neoplasia, of any type, with the exception of excised non metastatic non-melanoma skin cancer and previous malignant neoplasia cured since at least 5 years;~* Relapse of the end-stage renal disease on the transplanted kidney;~* Leucopenia, thrombocytopenia or severe anemia;~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Full Dose Myfortic® and Reduced Dose Neoral® (Type: EXPERIMENTAL): The administration of gradual dose increased to reach 1440 mg/day (V4) of enteric-coated mycophenolate sodium (Myfortic®, EC-MPS) with simultaneous dose reduction of micro emulsion cyclosporine (Neoral®, CsA-ME) given to maintenance kidney transplant patients previously treated with reduced-dose mycophenolate mofetil (MMF) and standard dose CsA-ME
- Standard Dose of Myfortic® and Standard Dose of CsA-ME (Type: ACTIVE_COMPARATOR): Patients received unchanged dose of Myfortic® (equimolar to the prior established dose MMF) and unchanged standard dose of CsA-ME.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues